Evidence map›Paper›PMID 26261255›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Yvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, Hua-Ling Tsai, Shannon R McCurdy, Jennifer A Kanakry, Gary L Rosner, Robert A Brodsky, Karlo Perica, B Douglas Smith and 16 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03992352 (Composite Health Assessment Risk Model), which is not on this map. Cited by 132 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 2 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03992352 completednot on this mapstarted 2019, after this paper: background citation

Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)

TypeobservationalSponsorCenter for International Blood and Marrow Transplant ResearchRan2019 to 2023Enrolled1,229ConditionsHematologic MalignancyArmsAge 60+ with planned HCT for Hematologic Malignancy
3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Pooled it
  2. Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  11. Trial
  12. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 1 institution in 1 country.

Yvette L KasamonAll authors: Johns Hopkins University, Baltimore, MD.
Javier Bolaños-MeadeAll authors: Johns Hopkins University, Baltimore, MD.
Gabrielle T PrinceAll authors: Johns Hopkins University, Baltimore, MD.
Hua-Ling TsaiAll authors: Johns Hopkins University, Baltimore, MD.
Shannon R McCurdyAll authors: Johns Hopkins University, Baltimore, MD.
Jennifer A KanakryAll authors: Johns Hopkins University, Baltimore, MD.
Gary L RosnerAll authors: Johns Hopkins University, Baltimore, MD.
Robert A BrodskyAll authors: Johns Hopkins University, Baltimore, MD.
Karlo PericaAll authors: Johns Hopkins University, Baltimore, MD.
B Douglas SmithAll authors: Johns Hopkins University, Baltimore, MD.
Douglas E GladstoneAll authors: Johns Hopkins University, Baltimore, MD.
Lode J SwinnenAll authors: Johns Hopkins University, Baltimore, MD.
Margaret M ShowelAll authors: Johns Hopkins University, Baltimore, MD.
William H MatsuiAll authors: Johns Hopkins University, Baltimore, MD.
Carol Ann HuffAll authors: Johns Hopkins University, Baltimore, MD.
Ivan BorrelloAll authors: Johns Hopkins University, Baltimore, MD.
Keith W PratzAll authors: Johns Hopkins University, Baltimore, MD.
Michael A McDevittAll authors: Johns Hopkins University, Baltimore, MD.
Ivana GojoAll authors: Johns Hopkins University, Baltimore, MD.
Amy E DezernAll authors: Johns Hopkins University, Baltimore, MD.
Satish ShanbhagAll authors: Johns Hopkins University, Baltimore, MD.
Mark J LevisAll authors: Johns Hopkins University, Baltimore, MD.
Leo LuznikAll authors: Johns Hopkins University, Baltimore, MD.
Richard F AmbinderAll authors: Johns Hopkins University, Baltimore, MD.
Ephraim J FuchsAll authors: Johns Hopkins University, Baltimore, MD.
Richard J JonesAll authors: Johns Hopkins University, Baltimore, MD. rjjones@jhmi.edu.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
TUMOR VACCINESP01CA015396 · NCI · JOHNS HOPKINS UNIVERSITY · PI JONES, RICHARD J · 1985 to 2016
$38.1M
TRAINING PROGRAM IN HEMATOLOGYT32HL007525 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ROBERT A BRODSKY · 1985 to 2026
$6.2M
Role of multiple myeloma cancer stem cells in clinical diseaseR01CA174951 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUFF, CAROL A · 2014 to 2018
$2.9M
MENTORING AND RESEARCH IN CANCER STEM CELLSK24CA198315 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI MATSUI, WILLIAM H · 2016 to 2020
$933k
NCATS NIH HHS UL1 TR001079NCI NIH HHS K24 CA198315NCI NIH HHS P01 CA015396NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA174951NHLBI NIH HHS T32 HL007525NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

purposeRecent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years. PATIENTS AND

methodsA retrospective analysis was performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who received NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide.

resultsThe median age was 61 years, with 115 patients (42%) age 50 to 59, 129 (48%) age 60 to 69, and 27 (10%) age 70 to 75 years. Overall, 84% of patients had intermediate- or high-/very high-risk disease. The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) were 3% and 8%, respectively. Patients in their 50s, 60s, and 70s had 6-month NRM probabilities of 8%, 9%, and 7%, respectively (P=.20). With a median follow-up of 4 years, corresponding 3-year progression-free survival probabilities were 39%, 35%, and 33% (P=.65), and corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (P=.66). Three-year progression-free survival probabilities were 40% in acute myeloid leukemia (n=65), 39% in aggressive non-Hodgkin lymphoma (n=83), and 37% in indolent or mantle-cell lymphoma (n=65). Older patient age was associated with a significantly higher risk of grade 2 to 4 acute GVHD but not grade 3 to 4 acute or chronic GVHD. No statistically significant associations were found between older age (relative to age 50 to 59 years or as a continuous variable) and NRM, relapse, or survival.

conclusionNMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years. In patients otherwise fit for BMT, the results support consideration of this approach despite advanced age.

Indexed as

Bone Marrow TransplantationHaplotypesTissue DonorsTransplantation ConditioningAgedAge FactorsAntineoplastic Agents, AlkylatingChemotherapy, AdjuvantCyclophosphamideDisease-Free SurvivalDisease ProgressionFemaleGraft vs Host DiseaseHematologic NeoplasmsHLA AntigensHumansAntineoplastic Agents, AlkylatingCyclophosphamideHLA Antigens

Identifiers

PMID26261255
PMCPMC4582145
OpenAlexW2148995443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.